Brief: Sartorius Stedim Biotech Eyes 60-85 Bps Underlying EBITDA Margin Increase Per Year From 2027
March 17 (Reuters) - Sartorius Stedim Biotech SA STDM.PA: SARTORIUS STEDIM BIOTECH SHARPENS STRATEGY WITH BIOPHARMA FOCUS AND SETS NEW MID-TERM GROWTH TARGETS TARGETS ORGANIC SALES REVENUE GROWTH OF 9-12% PER YEAR IN CONSTANT CURRENCIES FROM 2027 UNDERLYING EBITDA MARGIN EXPECTED TO INCREASE BY 60-85 BASIS POINTS PER YEAR FROM 2027 Source text: ID:nEQ80jnTRa Further company coverage: STDM.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))